STOCK TITAN

Novonix (NVX) grants performance rights, lifting director Michael O’Kronley’s holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Novonix Limited filed a Form 6-K that includes an ASX Appendix 3Y detailing a change in director interests for Michael O’Kronley. The filing records the issue of performance rights to the director following shareholder approval at the AGM held on 15 April 2026.

After this change, Michael O’Kronley holds 9,586,538 performance rights. The notice also confirms that the interests were not traded during a closed period, so no special trading clearance was required.

Positive

  • None.

Negative

  • None.
Director performance rights holding 9,586,538 performance rights Number of securities held after change for Michael O’Kronley
AGM approval date 15 April 2026 Date of shareholder approval for performance rights issue
Form type Form 6-K with Appendix 3Y Change of Director’s Interest Notice for Novonix Limited
performance rights financial
"No. of securities held after change | 9,586,538 performance rights"
Performance rights are conditional awards that give employees or executives the promise of receiving company shares or cash only if the business meets specific targets or survives for a set period. They work like a bonus you only get when certain goals are hit, so they matter to investors because they can increase the number of shares outstanding (dilution), signal management’s incentives and confidence in future results, and affect per-share earnings and valuation.
Appendix 3Y regulatory
"Appendix 3Y Change of Director’s Interest Notice"
listing rule 3.19A.2 regulatory
"We (the entity) give ASX the following information under listing rule 3.19A.2"
closed period regulatory
"Were the interests in the securities or contracts detailed above traded during a + closed period"

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of May, 2026

 

 

001-41208

 

 

(Commission File Number)

 

 

NOVONIX LIMITED

(Translation of registrant’s name into English)

 

Level 38

71 Eagle Street

Brisbane, QLD 4000 Australia

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20‑F or Form 40‑F.

Form 20-F Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 


 

 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

Exhibit 99.1

 

ASX Announcement (Final Director's Interest Notice) dated May 5, 2026

 

 

 

 

 

 

 


 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

NOVONIX LIMITED

 

 

 

 

 

 

By:

 

/s/ Robert Long

 

 

Robert Long

 

 

Chief Financial Officer

 

 

Date: May 5, 2026


Exhibit 99.1

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

Rule 3.19A.2

Appendix 3Y

 

Change of Director’s Interest Notice

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

 

Name of entity NOVONIX LIMITED

ABN 54 157 690 830

 

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director

MICHAEL O’KRONLEY

Date of last notice

15 December 2025

 

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

 

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest

DIRECT

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the relevant interest.

 

 

Date of change

5 May 2026

No. of securities held prior to change

3,723,971 performance rights

 

Class

Performance rights

Number acquired

5,862,567 performance rights

Number disposed

N/A

Value/Consideration

Note: If consideration is non-cash, provide details and estimated valuation

 

Estimated value of performance rights - $1,524,267 (based on closing share price on 4 May 2026).

 

+ See chapter 19 for defined terms.

 

01/01/2011 Appendix 3Y Page 1

 


Appendix 3Y

Change of Director’s Interest Notice

 

 

No. of securities held after change

9,586,538 performance rights

Nature of change

Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

Issue of performance rights following shareholder approval at the AGM held on 15 April 2026.

 

Part 2 – Change of director’s interests in contracts

 

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract

N/A

Nature of interest

 

 

 

Name of registered holder

(if issued securities)

 

 

Date of change

 

No. and class of securities to which interest related prior to change

Note: Details are only required for a contract in relation to which the interest has changed

 

 

Interest acquired

 

Interest disposed

 

Value/Consideration

Note: If consideration is non-cash, provide details and an estimated valuation

 

 

Interest after change

 

 

 

+ See chapter 19 for defined terms.

 

Appendix 3Y Page 2 01/01/2011

 


Exhibit 99.1

 

Appendix 3Y

Change of Director’s Interest Notice

 

 

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?

No.

If so, was prior written clearance provided to allow the trade to proceed during this period?

 

If prior written clearance was provided, on what date was this provided?

 

 

 

+ See chapter 19 for defined terms.

 

01/01/2011 Appendix 3Y Page 3

 


FAQ

What does Novonix (NVX) report in this Form 6-K filing?

Novonix reports a change in director interests via an ASX Appendix 3Y. Director Michael O’Kronley received performance rights that were approved by shareholders at the 15 April 2026 AGM, updating his total performance rights holding and regulatory disclosure.

How many performance rights does Novonix director Michael O’Kronley hold after the change?

After the change, Michael O’Kronley holds 9,586,538 performance rights. This figure reflects the updated position following the issue of new performance rights that were approved at Novonix’s annual general meeting held on 15 April 2026.

What triggered the change in Michael O’Kronley’s interests at Novonix (NVX)?

The change was triggered by the issue of performance rights to Michael O’Kronley. These performance rights were granted following shareholder approval at Novonix’s annual general meeting on 15 April 2026, and are recorded as a direct interest in the Appendix 3Y notice.

Were Novonix (NVX) director securities traded during a closed period?

The filing states the director’s interests were not traded during a closed period. The Appendix 3Y specifically answers “No” to trading during a closed period, so no prior written clearance for trading was required in connection with this change.

Is Michael O’Kronley’s interest in Novonix securities direct or indirect?

The Appendix 3Y identifies Michael O’Kronley’s interest as direct. This means the recorded 9,586,538 performance rights are held directly in his name, rather than through an intermediary entity or trust, clarifying how the director’s holdings are structured.

Filing Exhibits & Attachments

1 document